Drug Profile

Enarodustat - Japan Tobacco

Alternative Names: ENAROY; JTZ-951; SAL-0951

Latest Information Update: 12 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Japan Tobacco
Developer Japan Tobacco; JW Pharmaceutical; SalubrisBio
Class Acetic acids; Amides; Antianaemics; Pyridones; Small molecules; Triazoles
Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Anaemia
Phase II Chemotherapy-induced anaemia

Most Recent Events

18 Oct 2024 Shenzhen Salubris Pharmaceuticals completes a phase III trial in Anaemia in China (PO) (NCT06720233)
14 Sep 2024 Phase-II clinical trials in Chemotherapy-induced anaemia in China (PO) (NCT06737081)
17 Nov 2022 Preregistration for Anaemia in South Korea (PO) prior to November 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com